載入...
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
OBJECTIVE: Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monocl...
Na minha lista:
| 發表在: | Ann Clin Transl Neurol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BlackWell Publishing Ltd
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4435700/ https://ncbi.nlm.nih.gov/pubmed/26000318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.181 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|